Subscribe to Search results

Dr Morris McClelland explained that if a donor session was held at a factory or a workplace, they would have many more donors than if it were held in other community locations.

Published on:

Dr Morris McClelland told the Inquiry that policies adopted in London were followed by the Northern Ireland Blood Transfusion Service.

Published on:

According to Dr Morris McClelland's recollection, measures to prevent those with a history of intravenous drug use from giving blood included an interview and general assessment, but not anything more specific.

Published on:

Dr Morris McClelland told the Inquiry that the rapid uptake of red cell concentrates from 20% of the Belfast output to 75-80% in the space of three to four years was testament to the success of his and Dr Bharucha's work in persuading colleagues to use less whole blood and more red cell concentrates.

Published on:

In his evidence to the Inquiry, Dr Morris McClelland said that had they been asked, the Northern Ireland Blood Transfusion Service would have been able to reprioritise and increase cryoprecipitate production. However, no such request was made.

Published on:

Dr Morris McClelland told the Inquiry that he did not consider it to be his place to question the prescribing practice of Dr Elizabeth Mayne, the Belfast haemophilia director.

Published on:

The Belfast Regional Transfusion Centre began storing donor serum samples. Dr Morris McClelland explained to the Inquiry that this was influenced by Edinburgh.

Published on:

Dr Morris McClelland did not consider producing an AIDS leaflet for Belfast. He was aware a national leaflet was being produced and thought it was appropriate to follow the national approach.

Published on:

According to Dr Morris McClelland's recollection, an amended questionnaire with a question along the lines of "Have you read the AIDS leaflet" was introduced.

Published on:

In oral evidence to the Inquiry, Dr Brian McClelland stated that he never saw a follow-up proposal from Dr Barbara in relation to a joint study involving Edinburgh and the North London Blood Transfusion Centre.

Published on:

In oral evidence to the Inquiry, Dr Brian McClelland described the transfusion service as "losing sight of" NANBH for several years from 1983 due to preoccupation with HIV/AIDS.

Published on:

In oral evidence to the Inquiry, Dr Brian McClelland explained that ALT levels was only a small element of his proposal for a comprehensive study.

Published on:

In oral evidence to the Inquiry, Dr Brian McClelland accepted that nothing had really moved on since the beginning of the 1980s in relation to NANBH surrogate screening study.

Published on:

In oral evidence to the Inquiry, Dr Brian McClelland explained that the letter "Testing blood donors for Non-A, Non-B Hepatitis: irrational, perhaps, but inescapable" published in the Lancet was written partly out of extreme frustration at the fact that the appropriate epidemiological studies with donors and recipients had repeatedly not been done.

Published on:

In oral evidence to the Inquiry, Dr Brian McClelland agreed with the description of "decision paralysis" in relation to the situation with introduction of surrogate screening and undertaking of the respective study from the early 1980s through to the end of 1988.

Published on:

In his evidence, Dr Brian McClelland explained that he approached Wellcome because they were the only UK-based manufacturer and he was not optimistic about getting a positive response from US suppliers.

Published on:

There was a decision not to recall an implicated PFC batch 023110090. Dr Brian McClelland explained to the Inquiry in his oral evidence that recalling that batch would have led to a huge gap in the supply available to patients.

Published on:

Dr Brian McClelland told the Inquiry in his oral evidence that it emerged there was very little of PFC batch 023110090 to recall, apart from a few units at the Aberdeen Transfusion Centre. The rest had already been transfused.

Published on:

Dr Brian McClelland told the Inquiry in his oral evidence that in retrospect he should have attempted to find a laboratory in the US to identify which donation had infected the Protein Fractionation Centre batch 023110090.

Published on:

Dr Brian McClelland told the Inquiry in his oral evidence that the North London Regional Transfusion Centre set up a library of samples around 1981-1982.

Published on: